Jco precision oncology.

Drug-related pneumonitis as a result of novel cancer therapy provides new challenges for providers of cancer care in the era of precision medicine. Awareness of this emerging entity and knowledge of its manifestations and management guidelines are essential for state-of-the-art practice of clinical oncology. Here, we provide a detailed …This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. Research Funding: Ambry Genetics ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ...

DOI: 10.1200/PO.18.00356 JCO Precision Oncology - published online May 16, 2019 Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model Nathan A. Pennell, MD, PhD 1. x. Nathan A. Pennell. Search for articles …The field of behavioral economics recognizes that humans make decisions within the constraints of bounded rationality because of time and cognitive limits such as those observed with precision oncology. 1 This results in the use of heuristics (such as race), which may in turn increase individuals' reliance on cognitive biases (including …

Jul 28, 2020 · PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...

Jan 14, 2021 · DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome DOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...JCO Precision Oncology. Published by American Society of Clinical Oncology. Online ISSN: 2473-4284. Top-cited authors. Debyani Chakravarty. Memorial Sloan Kettering …Regrettably, the proportion of patients with advanced cancer outstrip the specialty PC workforce capacity. 20 In the United States, there are currently about 1,700-3,300 full-time equivalents of board-certified PC specialists, most of whom are not oncology-specific, and care for patients with other serious illness. 21,22 Unfortunately, the current pipeline for future PC physicians is narrow ...

JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision …

May 16, 2017 · Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ...

Aug 11, 2022 · Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy. 22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...Sep 29, 2021 · PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ... This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …DOI: 10.1200/PO.22.00107 JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022. PMID: 35977349. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors Matthew Dankner, BSc 1, 2, 3. x. Matthew Dankner. Search for articles by this …

DOI: 10.1200/PO.20.00109 JCO Precision Oncology no. 4 (2020) 898-911. Published online July 28, 2020. PMID: 35050760. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of ...This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …PURPOSE Hyperthermic intraperitoneal chemotherapy (HIPEC) confers a survival benefit in epithelial ovarian cancer (EOC) and in preclinical models. However, the molecular changes induced by HIPEC have not been corroborated in humans. PATIENTS AND METHODS A feasibility trial evaluated clinical and safety outcomes of HIPEC with cisplatin during optimal cytoreductive surgery (CRS) in patients with ...Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to the care of patients with cancer.

Jul 28, 2020 · PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ... OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.

PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we analyzed the implementation of a multidisciplinary PMed program ...Apr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ... When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing ConsiderationsDOI: 10.1200/PO.22.00694 JCO Precision Oncology no. 7 (2023) e2200694. Published online September 1, 2023. PMID: 37656949. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Milena Urbini, PhD 1. x. Milena Urbini. Search for articles by this author ...May 16, 2017 · Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ... Aug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 ...

Aug 11, 2022 · Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.

22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...

In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer.Sep 29, 2021 · PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ... Sep 13, 2017 · The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ... Jan 1, 2020 · JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe. David Cohn. Consulting or Advisory Role: …Professional English and Academic Editing Support. Submit to JCO PO. View/Change User Info. Institutions and Librarians. Subscribe to this Journal. Journal of Clinical Oncology. JCO Oncology Practice. JCO Global Oncology. JCO Clinical Cancer Informatics.This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ...DOI: 10.1200/PO.20.00280 JCO Precision Oncology no. 5 (2021) 215-226. Published online January 19, 2021. PMID: 34994597. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) ...WebJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post

DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryDOI: 10.1200/PO.22.00604 JCO Precision Oncology no. 7 (2023) e2200604. Published online July 12, 2023. PMID: 37437231. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies Akram Mesleh Shayeb, MD 1. x. Akram Mesleh Shayeb. Search for articles …A precision haircut is a style using techniques that create straight, dramatic lines and clean angles. Vidal Sassoon was the pioneer of precision haircutting, with the original philosophy of creating haircuts based on a client’s bone struct...Instagram:https://instagram. how does worthy workcrocs stocksbenziga probest us forex trading platform This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: TP Therapeutics, Nuvalent, Inc. Honoraria: Natera. b xbest dental insurance in south florida DOI: 10.1200/PO.21.00152 JCO Precision Oncology no. 5 (2021) 1639-1649. Published online October 22, 2021. Published online October 22, 2021. PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations options trading calculator Sep 29, 2021 · PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ... Jun 7, 2023 · The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ... DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017